Form 8-K - Current report:
SEC Accession No. 0001193125-25-286909
Filing Date
2025-11-19
Accepted
2025-11-19 06:28:03
Documents
16
Period of Report
2025-11-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d858713d8k.htm   iXBRL 8-K 45985
2 EX-2.1 d858713dex21.htm EX-2.1 22854
3 EX-10.1 d858713dex101.htm EX-10.1 917379
4 EX-99.1 d858713dex991.htm EX-99.1 135211
8 GRAPHIC g858713g1119012551128.jpg GRAPHIC 2847
  Complete submission text file 0001193125-25-286909.txt   1524018

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA alks-20251118.xsd EX-101.SCH 2853
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE alks-20251118_lab.xml EX-101.LAB 17926
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alks-20251118_pre.xml EX-101.PRE 11239
19 EXTRACTED XBRL INSTANCE DOCUMENT d858713d8k_htm.xml XML 3647
Mailing Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000
Business Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000 00-353-1-772-8000
Alkermes plc. (Filer) CIK: 0001520262 (see all company filings)

EIN.: 981007018 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35299 | Film No.: 251496592
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)